Regulation of TOR signaling in mammals

Enzymes

Volumn 27, Issue C, 2010, Pages 21-38

  Lamming, Dudley W ^a   Sabatini, David M ^a  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954922619     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-6047(10)27002-6     Document Type: Chapter

References (58)

1. Brown E.J., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
2. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78:35-43.
3. Sabers C.J., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822.
4. Loewith R., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002, 10:457-468.
5. Kim D.H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
6. Hara K., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110:177-189.
7. Chen E.J., Kaiser C.A. LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway. J Cell Biol 2003, 161:333-347.
8. Kim D.H., et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003, 11:895-904.
9. Sarbassov D.D., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-1302.
10. Jacinto E., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-1128.
11. Jones K.T., Greer E.R., Pearce D., Ashrafi K. Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol 2009, 7:e60.
12. Soukas A.A., Kane E.A., Carr C.E., Melo J.A., Ruvkun G. Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev 2009, 23:496-511.
13. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
14. Garcia-Martinez J.M., Alessi D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008, 416:375-385.
15. Frias M.A., et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 2006, 16:1865-1870.
16. Panasyuk G., et al. The mTORbeta splicing isoform promotes cell proliferation and tumorigenesis. J Biol Chem 2009, 284(45):30807-30814.
17. Sun C., Southard C., Di Rienzo A. Characterization of a novel splicing variant in the RAPTOR gene. Mutat Res 2009, 662:88-92.
18. Pearce L.R., et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 2007, 405:513-522.
19. Peterson T.R., et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
20. Sancak Y., et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007, 25:903-915.
21. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007, 9:316-323.
22. Long X., Ortiz-Vega S., Lin Y., Avruch J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 2005, 280:23433-23436.
23. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
24. Sancak Y., et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
25. Kim E., Goraksha-Hicks P., Li L., Neufeld T.P., Guan K.L. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008, 10:935-945.
26. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003, 5:578-581.
27. Inoki K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
28. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
29. Brugarolas J., et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004, 18:2893-2904.
30. Gwinn D.M., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008, 30:214-226.
31. Harrington L.S., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004, 166:213-223.
32. Tremblay F., Gagnon A., Veilleux A., Sorisky A., Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 2005, 146:1328-1337.
33. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002, 4:658-665.
34. Edinger A.L., Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002, 13:2276-2288.
35. Oshiro N., et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 2007, 282:20329-20339.
36. Wang L., Harris T.E., Roth R.A., Lawrence J.C. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007, 282:20036-20044.
37. Fonseca B.D., Smith E.M., Lee V.H., MacKintosh C., Proud C.G. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 2007, 282:24514-24524.
38. Madhunapantula S.V., Sharma A., Robertson G.P. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 2007, 67:3626-3636.
39. Yu F., Narasimhan P., Saito A., Liu J., Chan P.H. Increased expression of a proline-rich Akt substrate (PRAS40) in human copper/zinc-superoxide dismutase transgenic rats protects motor neurons from death after spinal cord injury. J Cereb Blood Flow Metab 2008, 28:44-52.
40. Ozes O.N., et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 2001, 98:4640-4645.
41. Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004, 14:1650-1656.
42. Avruch J., Long X., Ortiz-Vega S., Rapley J., Papageorgiou A., Dai N. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 2009, 296:E592-E602.
43. Binda M., et al. The Vam6 GEF controls TORC1 by activating the EGO complex. Mol Cell 2009, 35:563-573.
44. Jorgensen P., Rupes I., Sharom J.R., Schneper L., Broach J.R., Tyers M. A dynamic transcriptional network communicates growth potential to ribosome synthesis and critical cell size. Genes Dev 2004, 18:2491-2505.
45. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
46. Zeng Z., et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007, 109:3509-3512.
47. Guertin D.A., et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15:148-159.
48. Feldman M.E., et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
49. Thoreen C.C., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009, 284:8023-8032.
50. Garcia-Martinez J.M., et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009, 421:29-42.
51. Oudard S., et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009, 9:705-717.
52. Vellai T., Takacs-Vellai K., Zhang Y., Kovacs A.L., Orosz L., Muller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 2003, 426:620.
53. Kaeberlein M., et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 2005, 310:1193-1196.
54. Kapahi P., Zid B.M., Harper T., Koslover D., Sapin V., Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004, 14:885-890.
55. Medvedik O., Lamming D.W., Kim K.D., Sinclair D.A. MSN2 and MSN4 Link Calorie Restriction and TOR to Sirtuin-Mediated Lifespan Extension in Saccharomyces cerevisiae. PLoS Biol 2007, 5:e261.
56. Harrison D.E., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
57. Hansen M., Taubert S., Crawford D., Libina N., Lee S.J., Kenyon C. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell 2007, 6:95-110.
58. Selman C., et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.